Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:577 (22 September), doi:10.1136/bmj.39339.481667.3A
| The first 150 words of the full text of this article appear below. |
Barnes argues that using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control.1 Several studies support the use of budesonide/formoterol in the SMART (Symbicort (budesonide/formoterol) maintenance and reliever therapy) regimen.2 3 They have shown longer time to first exacerbation, reduced rate of severe exacerbations, and less inhaled corticosteroid dose, although with similar improvement in symptoms, peak flow rates, and quality of life in some studies. The concept looks promising, but some areas of concern remain.
The main concern is that all the above studies were conducted by the manufacturing firm (study design, data interpretation, data analysis, and publication). Three matching studies from the rival manufacturers of fluticasone/salmeterol have shown the opposite effect—stable dosing reducing exacerbation rate and improving symptom free days compared with the SMART regimen.4
Secondly, in all SMART studies patients needing more than 10 as needed inhalations were excluded, and this will have implication on therapy
Syed F Hussain, consultant respiratory physician
Kettering General Hospital, Kettering, Northamptonshire NN16 8UZ
Syed.Hussain@kgh.nhs.uk
Read all Rapid Responses